These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17473657)

  • 1. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib.
    Buckingham LE; Coon JS; Morrison LE; Jacobson KK; Jewell SS; Kaiser KA; Mauer AM; Muzzafar T; Polowy C; Basu S; Gale M; Villaflor VM; Bonomi P
    J Thorac Oncol; 2007 May; 2(5):414-22. PubMed ID: 17473657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
    Cappuzzo F; Hirsch FR; Rossi E; Bartolini S; Ceresoli GL; Bemis L; Haney J; Witta S; Danenberg K; Domenichini I; Ludovini V; Magrini E; Gregorc V; Doglioni C; Sidoni A; Tonato M; Franklin WA; Crino L; Bunn PA; Varella-Garcia M
    J Natl Cancer Inst; 2005 May; 97(9):643-55. PubMed ID: 15870435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors.
    Toffalorio F; de Marinis F; Conforti F; Spitaleri G; Catania C; Noberasco C; Lazzari C; Vecchio F; Stufano V; Barberis M; De Pas T
    J Thorac Oncol; 2015 Feb; 10(2):392-6. PubMed ID: 25611230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.
    Azuma K; Okamoto I; Kawahara A; Taira T; Nakashima K; Hattori S; Kinoshita T; Takeda M; Nakagawa K; Takamori S; Kuwano M; Ono M; Kage M
    J Thorac Oncol; 2012 Jan; 7(1):122-7. PubMed ID: 21892099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.
    Argiris A; Hensing T; Yeldandi A; Patel S; Raji A; Sturgis C; Masters G; Gooding W; Pins M; Kolesar J
    J Thorac Oncol; 2006 Jan; 1(1):52-60. PubMed ID: 17409827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
    J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
    Dongiovanni D; Daniele L; Barone C; Dongiovanni V; Fissore C; Sapino A; Macrì L; Bussolati G; Buffoni L; Gaspari F; Grillo R; Birocco N; Addeo A; Ciuffreda L; Schena M
    Lung Cancer; 2008 Jul; 61(1):73-81. PubMed ID: 18243402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
    Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
    J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
    Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
    Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors.
    Lazzari C; Spreafico A; Bachi A; Roder H; Floriani I; Garavaglia D; Cattaneo A; Grigorieva J; Viganò MG; Sorlini C; Ghio D; Tsypin M; Bulotta A; Bergamaschi L; Gregorc V
    J Thorac Oncol; 2012 Jan; 7(1):40-8. PubMed ID: 21964534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
    Dziadziuszko R; Witta SE; Cappuzzo F; Park S; Tanaka K; Danenberg PV; Barón AE; Crino L; Franklin WA; Bunn PA; Varella-Garcia M; Danenberg KD; Hirsch FR
    Clin Cancer Res; 2006 May; 12(10):3078-84. PubMed ID: 16707605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.
    Wu YL; Zhong WZ; Li LY; Zhang XT; Zhang L; Zhou CC; Liu W; Jiang B; Mu XL; Lin JY; Zhou Q; Xu CR; Wang Z; Zhang GC; Mok T
    J Thorac Oncol; 2007 May; 2(5):430-9. PubMed ID: 17473659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
    Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
    Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
    Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR mutations in patients with non small-cell lung cancer in Bulgaria and treatment with gefitinib.
    Damyanov D; Koynov K; Naseva E; Bichev S
    J BUON; 2015; 20(1):136-41. PubMed ID: 25778308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
    Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK
    J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.